UroGen Pharma Ltd. Pre-Tax Income
UroGen Pharma Ltd. (URGN) reported Pre-Tax Income of -$8.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-05
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$8.72M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$28.35M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$26.64M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$34.40M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$153.42M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$124.04M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$98.32M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$108.03M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.72M 10-Q · filed 2026-08-05 | -$37.07M 10-Q · filed 2026-08-05 | -$63.71M derived: sum of 3 quarters · filed 2026-08-05 | -$98.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$28.35M 10-Q · filed 2026-05-06 | -$54.98M derived: sum of 2 quarters · filed 2026-05-06 | -$89.39M derived: sum of 3 quarters · filed 2026-05-06 | -$138.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$26.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$61.04M derived: sum of 2 quarters · filed 2026-03-02 | -$109.97M derived: sum of 3 quarters · filed 2026-08-05 | -$153.42M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$34.40M 10-Q · filed 2025-11-06 | -$83.33M derived: sum of 2 quarters · filed 2026-08-05 | -$126.78M 10-Q · filed 2025-11-06 | -$161.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$48.92M 10-Q · filed 2026-08-05 | -$92.38M 10-Q · filed 2026-08-05 | -$127.24M derived: sum of 3 quarters · filed 2026-08-05 | -$150.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$43.45M 10-Q · filed 2026-05-06 | -$78.31M derived: sum of 2 quarters · filed 2026-05-06 | -$101.90M derived: sum of 3 quarters · filed 2026-05-06 | -$135.26M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$34.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$58.45M derived: sum of 2 quarters · filed 2026-03-02 | -$91.81M derived: sum of 3 quarters · filed 2026-03-02 | -$124.04M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$23.58M 10-Q · filed 2025-11-06 | -$56.95M derived: sum of 2 quarters · filed 2025-11-06 | -$89.18M 10-Q · filed 2025-11-06 | -$111.34M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$33.37M 10-Q · filed 2025-08-07 | -$65.60M 10-Q · filed 2025-08-07 | -$87.76M derived: sum of 3 quarters · filed 2025-08-07 | -$109.65M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$32.23M 10-Q · filed 2025-05-12 | -$54.39M derived: sum of 2 quarters · filed 2025-05-12 | -$76.28M derived: sum of 3 quarters · filed 2025-05-12 | -$100.36M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$22.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$44.05M derived: sum of 2 quarters · filed 2025-03-10 | -$68.13M derived: sum of 3 quarters · filed 2025-03-10 | -$98.32M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$21.89M 10-Q · filed 2024-11-06 | -$45.97M derived: sum of 2 quarters · filed 2024-11-06 | -$76.16M 10-Q · filed 2024-11-06 | -$104.34M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$24.08M 10-Q · filed 2024-08-13 | -$54.27M 10-Q · filed 2024-08-13 | -$82.45M derived: sum of 3 quarters · filed 2024-08-13 | -$107.58M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$30.19M 10-Q · filed 2024-05-13 | -$58.37M derived: sum of 2 quarters · filed 2024-05-13 | -$83.49M derived: sum of 3 quarters · filed 2024-05-13 | -$110.15M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$28.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$53.30M derived: sum of 2 quarters · filed 2024-03-14 | -$79.96M derived: sum of 3 quarters · filed 2024-03-14 | -$108.03M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$25.12M 10-Q · filed 2023-11-14 | -$51.78M derived: sum of 2 quarters · filed 2023-11-14 | -$79.85M 10-Q · filed 2023-11-14 | -$107.16M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$26.66M 10-Q · filed 2023-08-10 | -$54.73M 10-Q · filed 2023-08-10 | -$82.04M derived: sum of 3 quarters · filed 2023-08-10 | -$112.25M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$28.07M 10-Q · filed 2023-05-11 | -$55.38M derived: sum of 2 quarters · filed 2023-05-11 | -$85.59M derived: sum of 3 quarters · filed 2023-05-11 | -$111.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$27.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$57.53M derived: sum of 2 quarters · filed 2023-03-24 | -$83.44M derived: sum of 3 quarters · filed 2023-03-24 | -$109.37M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$30.21M 10-Q · filed 2022-11-10 | -$56.12M derived: sum of 2 quarters · filed 2022-11-10 | -$82.06M 10-Q · filed 2022-11-10 | -$109.21M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$25.91M 10-Q · filed 2022-08-11 | -$51.84M 10-Q · filed 2022-08-11 | -$79.00M derived: sum of 3 quarters · filed 2022-08-11 | -$107.81M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$25.93M 10-Q · filed 2022-05-10 | -$53.09M derived: sum of 2 quarters · filed 2022-05-10 | -$81.90M derived: sum of 3 quarters · filed 2022-05-10 | -$113.25M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$27.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$55.97M derived: sum of 2 quarters · filed 2022-03-21 | -$87.32M derived: sum of 3 quarters · filed 2022-03-21 | -$125.11M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$28.82M 10-Q · filed 2021-11-15 | -$60.16M derived: sum of 2 quarters · filed 2021-11-15 | -$97.96M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$31.35M 10-Q · filed 2021-08-04 | -$69.14M 10-Q · filed 2021-08-04 | ||
| 2019-12-31 | -$105.15M 10-K · filed 2021-03-18 | |||
| 2018-12-31 | -$75.53M 10-K · filed 2020-03-02 | |||
| 2017-12-31 | -$19.98M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | -$1.94M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | -$12.69M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |